Serum 1,25-Dihydroxyvitamin D in Bone Disease

Robert Steendijk, Marc K. Drezner, Mark R. Haussler, Charles R. Scriver, Theresa M. Reade, Hector F. Deluca, Alan J. Hamstra

Research output: Contribution to journalLetterpeer-review

7 Scopus citations


To the Editor: In a recent paper1 Scriver et al. stated that in patients with hypophosphatemic bone disease, active rickets is not observed, while serum phosphate is low and the level of 1α,25-dihydroxyvitamin D is normal. On the other hand, in patients with X-linked hypophosphatemia rachitic bone disease is present with similarly low levels of serum phosphate and decreased concentrations of 1α,25-dihydroxyvitamin D. This finding encouraged the authors to believe that a normal level of 1α,25-dihydroxyvitamin D prevents severe bone demineralization or, perhaps better, severe impairment of mineralization. It is possible to agree with this line of thought if the.

Original languageEnglish (US)
Pages (from-to)434-435
Number of pages2
JournalNew England Journal of Medicine
Issue number8
StatePublished - Feb 22 1979

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Serum 1,25-Dihydroxyvitamin D in Bone Disease'. Together they form a unique fingerprint.

Cite this